Posted in | Biosensors

PositiveID’s Interface for Continual Glucose Level Detection in Patients

PositiveID Corporation has recently filed a provisional patent application with the Patent and Trademark Office of the US regarding the interface between the interstitial space fluids of a patient and a resonant electromechanical drive powered by radio frequency (RF) for detecting a patient’s glucose levels continuously.

This interface depends on passive RF technology for monitoring in vivo glucose levels across an extended time period. The novel technology will implement effectively the glucose level RF detection technology as described by the earlier issued patent titled ‘Embedded Bio-Sensor System’ with patent number 7,125,382 of PositiveID.

The company has partnered with RECEPTORS LLC and is currently in Phase II of the development stage for the implantable glucose sensing microchip. This phase aims to optimize the sensing solution for glucose response in interstitial fluid matrix elements and blood and demonstrate the combination of these components in a reproducible and stable glucose sensor.

The implantable glucose-sensing microchip will incorporate a molecular sensor powered using RF technology. This sensor utilizes a combination of RF inductive power sensing, technology of micro electro mechanical system (MEMS), and Receptors’ developed analyte binding surface chemistry. The patent encompasses the utilization of RF technology for enabling sensing and communicating the variations in a mass like blood glucose levels to an external reader via an electromechanical drive enabled wireless molecular sensor.

PositiveID’s CEO and Chairman, Scott R. Silverman informed the transformational technology patent filing has further evidenced PositiveIDs significant ongoing progress for developing the glucose-sensing microchip. He clarified that filing of the patent application highlights the baseline of this microchip which will enable the company to create a product that could potentially transform the manner in which diabetics obtain their blood sugar readings, resulting in the elimination of the requirement to prick a patient’s fingers many times in a day.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback